USSTOCK.TODAY
Regular Market Log in Sign up

Bristol Myers Squibb Clinical Trial Participant Death and Large-Scale Pharmaceutical Deals

BioPharma Dive · ·by G4L

ZYME
ZYME Zymeworks BC Inc
$26.86 +3.15%
View chart & analysis →
  1. 1Bristol Myers Squibb stated that a clinical trial participant who received zola-cel died after 44 days.
  2. 2Gilead Sciences announced approximately $1.3 billion agreed to be paid to acquire Pepstar Therapeutics' experimental immune disease drug.
  3. 3Roche signed a deal including a $55 million upfront payment to Zymerworks and up to $718 million in additional payments upon achieving specific development and sales milestones.

So what's the key point?

A clinical trial participant for Bristol Myers Squibb has died. Gilead Sciences entered into a $1.3 billion deal, and Roche signed a contract with Zymerworks.

Source BioPharma Dive · View original ↗

Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →